Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria

被引:288
作者
Zinner, SH
机构
[1] Rhode Isl Hosp, Dept Med, Div Infect Dis, Roger Williams Med Ctr, Providence, RI 02903 USA
[2] Brown Univ, Sch Med, Providence, RI 02912 USA
关键词
D O I
10.1086/598620
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past 3 decades, considerable changes have occurred in the types of bacteria causing infection in febrile patients with neutropenia and cancer. Twenty years ago, gram-negative bacteria caused similar to 70% of bloodstream infections. As a probable consequence of long-dwelling intravascular devices, fluoroquinolone prophylaxis, and high-dose chemotherapy-induced mucositis, there has been a shift toward gram-positive coccal bacteremia, In most centers today, similar to 70% of bacteremic isolates are gram-positive cocci. Of potential concern is that antimicrobial-resistant gram-positive organisms are becoming increasingly frequent in patients with neutropenia. Fluoroquinolone-resistant Escherichia coli are being isolated from several cancer centers. Several "new" organisms, such as Stomatococcus mucilaginosus, Bacillus cereus, Leuconostoc species, Corynebacterium jeikeium, Rhodococcus species, Stenotrophomonas maltophilia, Moraxella catarrhalis, Burkholderia cepacia, and Bartonella species, now cause infections in these patients. Careful application of infection-control principles, judicious prophylaxis, appropriate evaluation of new antibiotics, and prompt effective therapy will maximize benefits for these patients.
引用
收藏
页码:490 / 494
页数:5
相关论文
共 38 条
[1]   SEPTICEMIA DUE TO STREPTOCOCCUS-MITIS IN NEUTROPENIC PATIENTS WITH ACUTE-LEUKEMIA [J].
ARNING, M ;
GEHRT, A ;
AUL, C ;
RUNDE, V ;
HADDING, U ;
SCHNEIDER, W .
BLUT, 1990, 61 (06) :364-368
[2]  
ASHER DP, 1991, REV INFECT DIS, V13, P1048
[3]   Penicillin-resistant Streptococcus mitis as a cause of septicemia with meningitis in febrile neutropenic children [J].
Balkundi, DR ;
Murray, DL ;
Patterson, MJ ;
Gera, R ;
ScottEmuakpor, A ;
Kulkarni, R .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1997, 19 (01) :82-85
[4]   Species belonging to the ''Streptococcus milleri'' group: Antimicrobial susceptibility and comparative prevalence in significant clinical specimens [J].
Bantar, C ;
Canigia, LF ;
Relloso, S ;
Lanza, A ;
Bianchini, H ;
Smayevsky, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (08) :2020-2022
[5]   CAPNOCYTOPHAGA BACTEREMIA IN A PATIENT WITH HODGKINS-DISEASE FOLLOWING BONE-MARROW TRANSPLANTATION - CASE-REPORT AND REVIEW [J].
BILGRAMI, S ;
BERGSTROM, SK ;
PETERSON, DE ;
HILL, DR ;
DAINIAK, N ;
QUINN, JJ ;
ASCENSAO, JL .
CLINICAL INFECTIOUS DISEASES, 1992, 14 (05) :1045-1049
[6]   Chryseobacterium meningosepticum: An emerging pathogen among immunocompromised adults - Report of 6 cases and literature review [J].
Bloch, KC ;
Nadarajah, R ;
Jacobs, R .
MEDICINE, 1997, 76 (01) :30-41
[7]   Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis [J].
Carratala, J ;
FernandezSevilla, A ;
Dominguez, FTMA ;
Gudiol, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (02) :503-505
[8]   ESCHERICHIA-COLI RESISTANT TO FLUOROQUINOLONES IN PATIENTS WITH CANCER AND NEUTROPENIA [J].
COMETTA, A ;
CALANDRA, T ;
BILLE, J ;
GLAUSER, MP .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (17) :1240-1241
[9]   PIPERACILLIN-TAZOBACTAM PLUS AMIKACIN VERSUS CEFTAZIDIME PLUS AMIKACIN AS EMPIRIC THERAPY FOR FEVER IN GRANULOCYTOPENIC PATIENTS WITH CANCER [J].
COMETTA, A ;
ZINNER, S ;
DEBOCK, R ;
CALANDRA, T ;
GAYA, H ;
KLASTERSKY, J ;
LANGENAEKEN, J ;
PAESMANS, M ;
VISCOLI, C ;
GLAUSER, MP ;
GIBSON, B ;
SANZ, M ;
HANN, IM ;
FOLLATH, F ;
FATIO, R ;
FERSTER, A ;
VANHOOF, A ;
VANLANDUYT, H ;
ARENDT, V ;
HEMMER, R ;
PEETERMANS, M ;
PADMOS, A ;
SEITANIDES, B ;
HATZIYANNI, M ;
LOPEZ, A ;
PORCELLINI, A ;
GREK, V ;
CABALLERO, D ;
TOGNI, P ;
GALLAGHER, JG ;
GARAVENTA, A ;
MASSIMO, L ;
SUGAR, A ;
LEGRAND, JC ;
OPPENHEIM, B ;
PETRIKKOS, G ;
BEYTOUT, J ;
NIKOSKELAINEN, J ;
SHAPIRO, M ;
ESTAVOYER, JM ;
KERN, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :445-452
[10]   Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer [J].
Cometta, AF ;
Calandra, T ;
Gaya, H ;
Zinner, SH ;
deBock, R ;
DelFavero, A ;
Bucaneve, G ;
Crokaert, F ;
Kern, WV ;
Klastersky, J ;
Langenaeken, J ;
Micozzi, A ;
Padmos, A ;
Paesmans, M ;
Viscoli, C ;
Glauser, MP ;
Martino, P ;
Caballero, D ;
Engelhard, D ;
Shapiro, M ;
Castagnola, E ;
Massimo, L ;
Giacchino, R ;
Sanz, M ;
Gigium, M ;
Carotenuto, M ;
Lopez, A ;
Andrien, JM ;
Paulus, R ;
Martino, B ;
Nobile, F ;
Togni, P ;
Ferster, A ;
Cudillo, L ;
Legrand, JC ;
Dinota, A ;
Cajozzo, A ;
Quintini, G ;
MartinezDalmau, A ;
Nosari, A ;
Bucaneve, GP ;
Cometta, A ;
Galazzo, M ;
Giddey, M ;
Bille, J ;
Blaser, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1108-1115